Wei Wei, PhD
Assistant Professor of Medicine (Medical Oncology)DownloadHi-Res Photo
Cards
Appointments
Medical Oncology and Hematology
Primary
Additional Titles
Interim Director of Biostatistics Shared Resource, Yale Cancer Center
Contact Info
Appointments
Medical Oncology and Hematology
Primary
Additional Titles
Interim Director of Biostatistics Shared Resource, Yale Cancer Center
Contact Info
Appointments
Medical Oncology and Hematology
Primary
Additional Titles
Interim Director of Biostatistics Shared Resource, Yale Cancer Center
Contact Info
About
Copy Link
Titles
Assistant Professor of Medicine (Medical Oncology)
Interim Director of Biostatistics Shared Resource, Yale Cancer Center
Biography
Wei Wei is an Associate Professor at Yale School of Medicine and Director of the Biostatistics Shared Resource at Yale Cancer Center. Dr. Wei's research area focuses on development of early phase clinical trial designs, with particular interest in cancer targeted and immunotherapeutic agents.
Last Updated on January 07, 2026.
Appointments
Medical Oncology and Hematology
Assistant ProfessorPrimary
Other Departments & Organizations
- Internal Medicine
- Medical Oncology and Hematology
- Yale Cancer Center
Education & Training
- PhD
- Medical University of South Carolina, Biostatistics (2016)
Research
Copy Link
Overview
Public Health Interests
Biomarkers; Cancer; Clinical Trials
ORCID
0000-0003-1263-5620
Research at a Glance
Yale Co-Authors
Frequent collaborators of Wei Wei's published research.
Harriet Kluger, MD
David Rimm, MD, PhD
Amit Mahajan, MD
Daniel Zelterman, PhD
Jan Philipp Bewersdorf, MD, FACP
Michael Kane, PhD, MA, MS
Publications
2025
Distinct T cell functions enable efficient immunoediting and prevent tumor emergence of developing sarcomas
Cheung J, Hunt B, Wahed S, Cheng E, Connolly K, Venkatesan S, Loza J, Bansal I, Fagerberg E, Kessler E, Riffard C, Buck J, Attanasio J, Borr E, Wei W, William I, Fitzgerald B, Joshi N. Distinct T cell functions enable efficient immunoediting and prevent tumor emergence of developing sarcomas. Cancer Cell 2025, 43: 2311-2326.e4. PMID: 41043437, PMCID: PMC12693725, DOI: 10.1016/j.ccell.2025.09.005.Peer-Reviewed Original ResearchAltmetricThe Maximum Negative Hypergeometric Distribution
Yu C, Prishwalko K, Blaha O, Kane M, Wei W, Esserman D, Zelterman D. The Maximum Negative Hypergeometric Distribution. Journal Of Statistical Theory And Practice 2025, 19: 88. DOI: 10.1007/s42519-025-00502-x.Peer-Reviewed Original ResearchFruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCO.
Dasari A, Eng C, Lonardi S, Garcia-Carbonero R, Masuishi T, Cremolini C, Ghiringhelli F, Hubbard J, Bekaii-Saab T, Jones J, Xu RH, Shen L, Xu J, Bai Y, Deng Y, Yuan Y, Wei W, Lin J, Chen L, Yang Z, Schelman WR, Qin S, Li J. Fruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCO. Eur J Cancer 2025, 227: 115641. PMID: 40795524, DOI: 10.1016/j.ejca.2025.115641.Peer-Reviewed Original ResearchClinical, sociodemographic, and facility-related determinants of immunotherapy use in metastatic triple-negative breast cancer
Ajjawi I, Rios A, Wei W, Park TS, Lustberg MB. Clinical, sociodemographic, and facility-related determinants of immunotherapy use in metastatic triple-negative breast cancer. Breast Cancer Res Treat. 2025 Jul;212(2):299-308. doi: 10.1007/s10549-025-07725-3. Epub 2025 May 15. PMID: 40369346.Peer-Reviewed Original ResearchClinical, sociodemographic, and facility-related determinants of immunotherapy use in metastatic triple-negative breast cancer
Ajjawi I, Rios A, Wei W, Park T, Lustberg M. Clinical, sociodemographic, and facility-related determinants of immunotherapy use in metastatic triple-negative breast cancer. Breast Cancer Research And Treatment 2025, 212: 299-308. PMID: 40369346, DOI: 10.1007/s10549-025-07725-3.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsMetastatic triple-negative breast cancerMetastatic triple-negative breast cancer patientsNational Cancer DatabaseTriple-negative breast cancerImmunotherapy useRetrospective cohort studyBreast cancerLog-rank testCox proportional hazards regressionHigher Charlson comorbidity scoreCharlson comorbidity scoreMultivariate logistic regressionProportional hazards regressionLow likelihoodOverall survivalCancer DatabaseImmunotherapy recipientsSurvival outcomesImmunotherapyDiagnosis yearComorbidity scoreBlack raceHazards regressionPatientsHispanic ethnicityClinical, Sociodemographic, and Facility-Related Factors Influencing HER2-Targeted Therapy in Metastatic Hormone Receptor-Negative, HER2-Positive Breast Cancer
Ajjawi I, Rios A, Wei W, Park TS, Lustberg MB. Clinical, Sociodemographic, and Facility-Related Factors Influencing HER2-Targeted Therapy in Metastatic Hormone Receptor-Negative, HER2-Positive Breast Cancer. Cancers (Basel). 2025 May 6;17(9):1579. doi: 10.3390/cancers17091579. PMID: 40361505; PMCID: PMC12072055.Peer-Reviewed Original ResearchClinical, Sociodemographic, and Facility-Related Factors Influencing HER2-Targeted Therapy in Metastatic Hormone Receptor-Negative, HER2-Positive Breast Cancer
Ajjawi I, Rios A, Wei W, Park T, Lustberg M. Clinical, Sociodemographic, and Facility-Related Factors Influencing HER2-Targeted Therapy in Metastatic Hormone Receptor-Negative, HER2-Positive Breast Cancer. Cancers 2025, 17: 1579. PMID: 40361505, PMCID: PMC12072055, DOI: 10.3390/cancers17091579.Peer-Reviewed Original ResearchAltmetricConceptsHER2-Targeted TherapyHormone receptor-negativeRetrospective cohort studyBreast cancer patientsTherapy useBreast cancerHER2-positiveReceptor-negativeSurvival outcomesCancer patientsHER2-positive breast cancerTherapy utilizationLog-rank testCox proportional hazards regressionFacility-related barriersMultivariate logistic regressionProportional hazards regressionHR-/HER2Overall survivalTherapy recipientsLower mortality riskHER2 targetingBlack raceHazards regressionMedicare insurancePhase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Bhatia A, Mehra R, Bauman J, Khan S, Wei W, Neumeister V, Sandoval‐Schaefer T, Alpaugh R, Lango M, Rimm D, Ridge J, Burtness B. Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck. Head & Neck 2025, 47: 2373-2382. PMID: 40166973, DOI: 10.1002/hed.28152.Peer-Reviewed Original ResearchThis study investigates the efficacy of adding erlotinib to chemotherapy and cetuximab for head and neck cancer, showing improved response rates, highlighting potential for dual EGFR targeting in treatment.Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases
Weiss S, Djureinovic D, Wei W, Tran T, Austin M, Markowitz J, Eroglu Z, Khushalani N, Hegde U, Cohen J, Sznol M, Anderson G, Johnson B, Piteo C, Mahajan A, Adeniran A, Jilaveanu L, Goldberg S, Chiang V, Forsyth P, Kluger H. Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases. Journal Of Clinical Oncology 2025, 43: 1685-1694. PMID: 40048689, PMCID: PMC12058415, DOI: 10.1200/jco-24-02219.Peer-Reviewed Original ResearchCitationsAltmetricConceptsMelanoma brain metastasesOverall survivalBrain metastasesAnti-vascular endothelial growth factor therapyMedian intracranial progression-free survivalFour-year OS ratesIntracranial progression-free survivalResponse rateCirculating angiopoietin-2Median overall survivalTrial of pembrolizumabYears of pembrolizumabDose of bevacizumabProgression-free survivalPhase II trialGrowth factor therapyAdverse event ratesAssociated with responseOS ratesPD-1Radiation necrosisLocal therapyOn-therapyMetastatic tumorsFactor therapyStatistical considerations for evaluating treatment effect under various non-proportional hazard scenarios
Zhang X, Greene E, Blaha O, Wei W. Statistical considerations for evaluating treatment effect under various non-proportional hazard scenarios. Statistical Methods In Medical Research 2025, 34: 986-1000. PMID: 39930911, PMCID: PMC12582275, DOI: 10.1177/09622802241313297.Peer-Reviewed Original ResearchAltmetricConceptsNon-proportional hazardsType I error rateAnalysis of time-to-event outcomesTime-to-event outcomesComparison of statistical methodsGeneralized gamma modelMaxCombo testGamma modelF modelOverall treatment effectTreatment effectsReal dataSurvival probabilityGeneralizationOncology trialsPublished oncology trials
Academic Achievements & Community Involvement
Copy Link
Activities
activity Leukemia & Lymphoma Society
2025 - PresentPeer Review Groups and Grant Study SectionsGrant Revieweractivity Design and Implementation of Clinical Trials
11/17/2025 - 11/21/2025LectureWinn-AACR Design and Implementation of Clinical Trials WorkshopDetailsAlbuquerque, NM, United StatesSponsored by American Association for Cancer ResearchCollaborators
Teaching & Mentoring
Copy Link
Mentoring
Jinping Liang
Graduate student2025 - PresentMichelle Song
Graduate student2025 - PresentYunhe Liu
Graduate student at YSPH2022 - 2024Yunxuan Zhang
Graduate student at YSPH2022 - 2023
Willing and Available to Mentor
- Faculty
- Clinicians
- Students
- Residents
- Clinical Fellows
- Postdoctoral Researchers
News
Copy Link
News
Get In Touch
Copy Link
Contacts
Email